Sun Pharmaceutical Industries Ltd. - Research Center
524715 SUNPHARMA Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 22 | Dec' 21 | Sep' 21 | Jun' 21 | Mar' 21 | |
|---|---|---|---|---|---|
| Sales | 4,006.88 | 3,770.66 | 4,143.15 | 3,325.95 | 3,159.64 |
| Operating profit | 999.84 | 656.39 | 864.27 | 631.49 | 680.25 |
| Interest | 91.19 | 85.47 | 103.98 | 105.72 | 102.73 |
| Gross profit | 1,209.06 | 876.15 | 1,044.56 | 583.57 | 612.39 |
| EPS (Rs) | -5.36 | 2.15 | 3.37 | 1.75 | 1.36 |
Quarterly
results in details
| Mar' 22 | Dec' 21 | Sep' 21 | Jun' 21 | Mar' 21 | |
|---|---|---|---|---|---|
| Other income | 300.41 | 305.23 | 284.27 | 57.80 | 34.87 |
| Stock adjustment | -150.13 | -25.10 | 48.42 | -82.46 | -270.26 |
| Raw material | 1,286.24 | 1,127.05 | 1,092.30 | 993.95 | 1,124.16 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 497.94 | 501.79 | 509.07 | 489.99 | 424.62 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,372.99 | 1,510.53 | 1,629.09 | 1,292.98 | 1,200.87 |
| Provisions made | - | - | - | - | - |
| Depreciation | 354.14 | 355.24 | 333.64 | 150.92 | 151.76 |
| Taxation | 486.17 | 5.48 | -98.15 | 13.35 | 43.68 |
| Net profit / loss | -1,286.21 | 515.43 | 809.07 | 419.30 | 327.39 |
| Extra ordinary item | -1,654.96 | - | - | - | -89.56 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 239.93 | 239.93 | 239.93 | 239.93 | 239.93 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 24.95 | 17.41 | 20.86 | 18.99 | 21.53 |
| GPM (%) | 28.07 | 21.50 | 23.59 | 17.25 | 19.17 |
| NPM (%) | -29.86 | 12.65 | 18.27 | 12.39 | 10.25 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis